Serum-derived bovine immunoglobulin treatment in COVID-19 is associated with faster resolution of symptoms: A randomized pilot clinical trial.

Autor: Utay NS; Department of Internal Medicine, Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Güerri-Fernández R; Department of Infectious Diseases Hospital del Mar., Univ. Pompeu Fabra, Barcelona, Spain., Gharakhanian S; CIC: Cambridge Innovation Center, Pharmaceutical Medicine & Infectious Diseases, Shahin Gharakhanian MD Consulting LLC, One Broadway, Cambridge, Massachusetts, USA., Asmuth DM; Department of Internal Medicine, University of California, Davis, Sacramento, California, USA., Contreras M; Proliant Health & Biologicals, Ankeny, Iowa, USA., Kunkler C; Proliant Health & Biologicals, Ankeny, Iowa, USA., Detzel CJ; Proliant Health & Biologicals, Ankeny, Iowa, USA., Warner CD; Proliant Health & Biologicals, Ankeny, Iowa, USA.

Publikováno v: Journal of medical virology [J Med Virol] 2024 Oct; Vol. 96 (10), pp. e70005.

PB0364 Glycoprotein VI-Targeted Antiplatelet Therapy with Glenzocimab is Safe in Patients Exposed to Current Antithrombotic and Fibrinolytic Drugs

Autor: Jandrot-Perrus, M., Pottecher, J., Toledano, E., Commenducci, A., Meilhoc, A., Gharakhanian, S., Avenard, G., Pletan, Y., Binay, S., Mazighi, M.

Publikováno v: In Research and Practice in Thrombosis and Haemostasis October 2023 7 Supplement 2

Hypogonadism in HIV infection: time to fine-tune clinical monitoring of persons with HIV?

Autor: Gharakhanian S; Infectious Diseases, Pharmaceutical Medicine, Shahin Gharakhanian MD Consulting LLC, CIC: Cambridge Innovation Center, Cambridge, Massachusetts, USA., De Wit S; Department of Infectious Diseases, Free University of Brussels, Saint-Pierre University Hospital, Brussels, Belgium.

Publikováno v: AIDS (London, England) [AIDS] 2022 Jul 01; Vol. 36 (8), pp. 1197-1199.

Potential use of serum-derived bovine immunoglobulin/protein isolate for the management of COVID-19.

Autor: Utay NS; Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA., Asmuth DM; Department of Internal Medicine, University of California Davis, Sacramento, California, USA., Gharakhanian S; Pharmaceutical Medicine & Infectious Diseases, Shahin Gharakhanian MD Consulting LLC, Cambridge Innovation Center (CIC), Cambridge, Massachusetts, USA., Contreras M; Department of Research and Development, Entera Health, LLC, Ankeny, Iowa, USA., Warner CD; Department of Research and Development, Entera Health, LLC, Ankeny, Iowa, USA., Detzel CJ; Department of Research and Development, Entera Health, LLC, Ankeny, Iowa, USA.

Publikováno v: Drug development research [Drug Dev Res] 2021 Nov; Vol. 82 (7), pp. 873-879. Date of Electronic Publication: 2021 Jun 10.

HIV therapeutic vaccine enhances non-exhausted CD4 ⁺ T cells in a randomised phase 2 trial.

Autor: Vieillard V; 1Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France., Combadière B; 1Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France., Tubiana R; 2AP-HP Pitié-Salpêtrière, Paris, France.; 3Sorbonne Université, UPMC Univ Paris 06, Inserm, Pierre Louis Institute of Epidemiology and Public Health, Paris, France., Launay O; 4AP-HP Cochin, Paris, France., Pialoux G; 5AP-HP Tenon, Paris, France., Cotte L; 6Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France., Girard PM; 7AP-HP Saint-Antoine, Paris, France., Simon A; 2AP-HP Pitié-Salpêtrière, Paris, France.; 3Sorbonne Université, UPMC Univ Paris 06, Inserm, Pierre Louis Institute of Epidemiology and Public Health, Paris, France., Dudoit Y; 2AP-HP Pitié-Salpêtrière, Paris, France., Reynes J; 8Hôpital Gui de Chauliac, Montpellier, France.; 9Unité Mixte Internationale 'TransVIHMI', IRD UMI233, Inserm U1175, Université de Montpellier, Montpellier, France., Rockstroh J; Universität Klinikum Bonn, Bonn, Germany., Garcia F; 11Hospital Clínic, Barcelona, Spain., Gatell J; 12ViiV Healthcare, Brentford, UK., Devidas A; 13Centre hospitalier Sud Francilien, Corbeil-Essonne, France., Yazdanpanah Y; 14AP-HP Bichat, Paris, France., Weiss L; 15AP-HP Hôpital Européen Georges Pompidou, Paris, France.; Université Paris Descartes, Sorbonne Paris-Cité; Inserm, Paris, France., Fätkenheuer G; 17Department 1 for Internal Medicine, University Hospital of Cologne, Cologne, Germany.; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany., Autran B; 1Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.; 2AP-HP Pitié-Salpêtrière, Paris, France., Joyeux D; Minka Therapeutics, Paris, France., Gharakhanian S; Pharmaceutical Medicine & Infectious Diseases, CIC: Cambridge Innovation Center, Cambridge, MA USA., Debré P; 1Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.; 2AP-HP Pitié-Salpêtrière, Paris, France., Katlama C; 2AP-HP Pitié-Salpêtrière, Paris, France.; 3Sorbonne Université, UPMC Univ Paris 06, Inserm, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.

Publikováno v: NPJ vaccines [NPJ Vaccines] 2019 Jun 03; Vol. 4, pp. 25. Date of Electronic Publication: 2019 Jun 03 (Print Publication: 2019).